News About: Pharm. Affairs
Pradaxa and Eliquis will get insurance benefits for deep vein thrombosis
Insurance benefits of ‘Pradaxa’ and ‘Eliquis’ will be available on treating and preventing reoccurrence of deep vein thrombosis (DVT) and pulmonary Embolism (PE).
The Ministry of Health and Welfare made an official a...
The domestic launch of the stomach cancer target agent ‘Cyramza’ is visualized
The fact that a new target agent for stomach cancer is visualized attracted the pharmaceutical industry.
According to the Ministry of Food and Drug Safety on the 15th, the Lilly Korea’s stomach cancer target agent ‘C...
The completion of domestic dementia patches and pharmaceutical technologies threats original products
“They do not make new drugs, but definitely are good at developing medicines using new substances.”
Domestic pharmaceutical companies are showing capability on developing drugs with their experience of developing gen...
Viread and Baraclude are expecting a competition against generics
The benefit range of the chronic hepatitis type B treatment ‘Viread (generic name: tenofovir)’ has been extended. This would be a favorable condition for the product prior to competition against its competing drug ‘Ba...
Celgene’s Abraxane INJ extended its indication to lung cancer after pancreatic cancer
Celgene Korea (CEO Ah-kyung Kim), a global pharmaceutical company specializing in cancer, unveiled on the 31st that its ‘Abraxane INJ’ acquired an additional approval to add a non-small cell lung cancer indication fro...
The average medical expense for chronic diseases is monthly KRW 10,500 while man pay KRW 500 more
It is known that monthly medicine expenses for chronic diseases are KRW 10,500 in average.
According to the ‘2012 Basic Analysis Report for the Korea Health Panel (II)’ co-conducted by the National Health Insurance S...
Fillers and Botulinum Toxin become major with their KRW 200 billion market
As entering the KRW 200 billion level, the market of fillers and Botulinum Toxin rises as one of the major markets.
According to the pharmaceutical industrial report revealed recently by Hana Daetoo Securities, the s...
The most prescribed pharmaceutical product for the Patent Linkage System is ‘Januvia’
After the enforcement of the Patent Linkage System, it is known that diabetes treatments, Januvia and Janumet, are the original products that generic companies are keeping their eyes on.
According to the informed pha...
The prescription rate of Champix in antismoking treatments was 72.1% “patient-sharing medical costs are excessive”
It is known that 7 of 10 patients prescribed antismoking treatments as a part of the Smoking Cessation Supporting Project that has been conducted since the last February were prescribed ‘Champix’.
According to Assemb...
“By 2030, the industry will lack 10,000 doctors and 15,000 pharmacists”
It is expected that the number of healthcare and medical personnel will be short by approximately 120 thousand people at most in 2030. An analysis showed that the industry will lack 10,000 people in doctors and 15,000...
